The two greatest reasons TTPH remains in the dumps (aside from no FDA word) is:
1) There's currently no 'following' to bring awareness to TTPH.
I bet if SA wrote an article reminding the public of TTPH's cash on hand vs marketcap, and highlighted the IGNITE 1 success, as well as the need for eravacycline, and the limited other bio's in this area of specialty, the pps would likely near double.
2) Lack of a 'following' allows the algo'bot to mimic IBB.
Put the two side by side on a 1 minute chart and you'll see how closely they trade in unison, most of the time.